The soon-to-be-solved protein problem that will accelerate drug discovery

Riskgaming

We’ve known for decades that one of the key mechanisms of biology — and of life itself — is the binding of molecules to proteins. Once bound, proteins change shape and thus their function, allowing our bodies to adapt and change their molecular machinery as needed for survival. The challenge that remains unsolved is to predict — across billions of potential proteins and a similar number of molecules — how those proteins change and how they might interact with each other.

The fervent hope of many scientists and entrepreneurs is that artificial intelligence coupled with experimental and synthetic datasets, may finally unlock this critical piece of the biological puzzle, ushering in a new wave of therapeutics.

My guest today is one of those science entrepreneurs, Laksh Aithani, the co-founder and CEO of Charm Therapeutics. He’s made cancer the focus of his work, and through Charm and his team, is building expansive datasets to develop AI models that can predict the 3D shape of proteins.

Alongside host Danny Crichton and my Lux colleague Tess van Stekelenburg, we explore protein folding’s past, present and future, the utility and risks of synthetic data in biological research, how much money and time we might expect for future drug discovery, what individualized medicine might look like decades from now, and how new grads can get into the field as the century of biology kicks off.